April 2 - 3, 2020
Hilton La Jolla Torrey Pines
La Jolla, CA

Agenda

Thursday April 2, 2020

11:00

 

Registration

1:00 - 1:05

 

Introduction
Jacob M. Rowe, MD, Co-Chairman

 

Session 1:  Advances in Myelodysplasia
Moderators: Stephen D. Nimer, MD, Raphael Bejar, MD, PhD

1:05 - 1:20

 

How important is genetic predisposition in myelodysplasia?
Akiko Shimamura, MD, PhD

1:20 - 1:30

 

Discussion

1:30 - 1:45

 

How do molecular features guide therapy in myelodysplasia?
Hetty E. Carraway, MD

1:45 - 1:55

 

Discussion

1:55 - 2:10

 

Novel therapeutic strategies in chronic myelomonocytic leukemia
Mrinal S. Patnaik, MBBS

2:10 - 2:20

 

Discussion

2:20 - 2:35

 

Is there a best therapy after failure of hypomethylating agents for MDS?
Amer Zeidan, MBBS

2:35 - 2:45

 

Discussion

2:45 - 3:05

 

Break

 

Session 2:  Novel Strategies in ALL
Moderators: Wendy Stock, MD, Mignon Loh, MD

3:10 - 3:25

 

CAR-T in adult ALL:  When and for whom?
Noelle V. Frey, MD, MSCE

3:25 - 3:35

 

Discussion

3:35 - 3:50

 

How to manage an older adult with Ph-negative ALL
Jae H. Park, MD

3:50 - 4:00

 

Discussion

4:00 - 4:15

 

Are we making any progress in T-cell ALL?
Adolfo Ferrando, MD, PhD

4:15 - 4:25

 

Discussion

4:25 - 4:40

 

Have any treatment strategies in Ph-like ALL been shown to be effective?
Stephen P. Hunger, MD

4:40 - 4:50

 

Discussion

4:50 - 5:15

 

Young Investigator Award

5:15 - 6:00

 

Poster Session/Reception

 

Friday April 3, 2020

7:00 – 7:40

 

Registration and Breakfast

7:45 – 7:50

 

Introduction
Jacob M. Rowe, MD, Co-Chairman

 

Session 1: Basic Biology
Moderators: R. Coleman Lindsley, MD, PhD, Marshall A. Lichtman, MD

7:50 – 8:05

 

What factors contribute to long-term survival of hematopoietic stem cells?
John E. Dick, PhD, FRS

8:05 – 8:15

 

Discussion

8:15 – 8:30

 

How do spliceosome mutations contribute to AML?
Omar I. Abdel-Wahab, MD

8:30 – 8:40

 

Discussion

8:40 – 8:55

 

What are the molecular mechanisms driving the switch from MPNs to leukemia?
Ronald Hoffman, MD

8:55 – 9:05

 

Discussion

9:05 – 9:25

 

Break

 

Session 2: Therapy of Induction, Post-remission and Relapse
Moderators: Richard Stone, MD, Elihu H. Estey, MD

9:30 – 9:45

 

Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?
Mark Levis, MD, PhD

9:45 – 9:55

 

Discussion

9:55 – 10:10

 

Can one overcome p53 mutations in AML?
David A. Sallman, MD

10:10 – 10:20

 

Discussion

10:20 – 10:35

 

Is there a role for checkpoint inhibitors in AML?
Naval G. Daver, MD

10:35 - 10:45

 

Discussion

10:45 - 11:00

 

Which novel agents will have a clinically meaningful impact in AMLat diagnosis?
Alexander E.Perl, MD, MS

11:00 - 11:10

 

Discussion

11:10 - 11:25

 

Why is there no standard of care for relapsed AML?
Ehab L. Attalah, MD

11:25 – 11:35

 

Discussion

11:35 – 12:35

 

Lunch

 

Session 3: Bone Marrow Transplantation
Moderators: Armand Keating, MD, Nelson Chao, MD, MBA

12:40 – 12:55

 

The ever-increasing upper age for transplant:  Is this evidence-based?
Daniel J. Weisdorf, MD

12:55 – 1:05

 

Discussion

1:05 – 1:20

 

Are we making any progress in the management of a patient with chronic GvHD at 12 months?
Mary E. Flowers, MD

1:20 – 1:30

 

Discussion

1:30 – 1:45

 

How to overcome graft failure in haploidentical transplantation?
Xiao-JunHuang, MD

1:45 – 1:55

 

Discussion

1:55 – 2:10

 

Is there a role for HMAs as post-transplant maintenance?
Frederick R. Appelbaum, MD

2:10 – 2:20

 

Discussion

2:20 – 2:40

 

Break

 

Session 4: Supportive Care and Perspective
Moderators: Beverly S. Mitchell, MD, Kenneth Kaushansky, MD

2:45 – 3:00

 

Why are there controversies in the recent WHO classification of AML?
Robert P. Hasserjian, MD

3:00 – 3:10

 

Discussion

 

Ernest Beutler Memorial Lecture

3:10 – 3:20

 

Introduction of Connie Eaves
Frederick R. Appelbaum, MD

3:20 – 3:50

 

Stem cells and leukemogenesis
Connie J. Eaves, PhD, FRS(C)

3:50 – 3:55

 

Discussion

3:55 – 4:00

 

Concluding Remarks and Close
Martin S. Tallman, MD, Co-Chairman